Viral evasion and challenges of hepatitis C virus vaccine development

Current Opinion in Virology

Volumn 20, Issue , 2016, Pages 55-63

  Pierce, Brian G ^a   Keck, Zhen Yong ^b   Foung, Steven KH ^b  

^a UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD81 ANTIGEN; GLYCOPROTEIN E2; HEPATITIS C VACCINE; NEUTRALIZING ANTIBODY; T LYMPHOCYTE RECEPTOR; VIRUS VACCINE;

ANTIBODY COMBINING SITE; ANTIBODY RESPONSE; ANTIGEN BINDING; ANTIGEN RECOGNITION; DRUG DESIGN; EPITOPE MAPPING; HUMAN; IMMUNE EVASION; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW; VIRAL CLEARANCE; VIRUS NEUTRALIZATION; DRUG DEVELOPMENT; GENETIC VARIATION; GENETICS; HEPACIVIRUS; IMMUNOLOGY; ISOLATION AND PURIFICATION; PROCEDURES; TRENDS;

DRUG DISCOVERY; GENETIC VARIATION; HEPACIVIRUS; HUMANS; VIRAL VACCINES;

EID: 84988358456     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2016.09.004     Document Type: Review

References (98)

1. 1 Mohd Hanafiah, K., Groeger, J., Flaxman, A.D., Wiersma, S.T., Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 57 (2013), 1333–1342.
2. 2 Ly, K.N., Hughes, E.M., Jiles, R.B., Holmberg, S.D., Rising mortality associated with hepatitis C virus in the United States, 2003–2013. Clin Infect Dis 62 (2016), 1287–1288.
3. 3 Choo, Q.L., Kuo, G., Weiner, A.J., Overby, L.R., Bradley, D.W., Houghton, M., Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244 (1989), 359–362.
4. 4 Walker, C.M., Grakoui, A., Hepatitis C virus: why do we need a vaccine to prevent a curable persistent infection?. Curr Opin Immunol 35 (2015), 137–143.
5. 5 Fauvelle, C., Colpitts, C.C., Keck, Z.Y., Pierce, B.G., Foung, S.K., Baumert, T.F., Hepatitis C virus vaccine candidates inducing protective neutralizing antibodies. Expert Rev Vaccines, 2016, 1–10.
6. 6 Lontok, E., Harrington, P., Howe, A., Kieffer, T., Lennerstrand, J., Lenz, O., McPhee, F., Mo, H., Parkin, N., Pilot-Matias, T., et al. Hepatitis C. virus drug resistance-associated substitutions: state of the art summary. Hepatology 62 (2015), 1623–1632.
7. 7 Gray, E., O'Leary, A., Stewart, S., Bergin, C., Cannon, M., Courtney, G., Crosbie, O., De Gascun, C.F., Fanning, L.J., Feeney, E., et al. High mortality during direct acting antiviral therapy for hepatitis C patients with Child's C cirrhosis: results of the Irish Early Access Programme. J Hepatol, 2016.
8. 8 Cox, A.L., MEDICINE. Global control of hepatitis C virus. Science 349 (2015), 790–791.
9. 9 Cashman, S.B., Marsden, B.D., Dustin, L.B., The humoral immune response to HCV: understanding is key to vaccine development. Front Immunol, 5, 2014, 550.
10. 10 Dunlop, J., Owsianka, A., Cowton, V., Patel, A., Current and future prophylactic vaccines for hepatitis C virus. Vaccine Dev Therapy, 2015, 31–44.
11. 11 Saito, K., Ait-Goughoulte, M., Truscott, S.M., Meyer, K., Blazevic, A., Abate, G., Ray, R.B., Hoft, D.F., Ray, R., Hepatitis C virus inhibits cell surface expression of HLA-DR, prevents dendritic cell maturation, and induces interleukin-10 production. J Virol 82 (2008), 3320–3328.
12. 12 Tasaka-Fujita, M., Sugiyama, N., Kang, W., Masaki, T., Murayama, A., Yamada, N., Sugiyama, R., Tsukuda, S., Watashi, K., Asahina, Y., et al. Amino acid polymorphisms in hepatitis C virus core affect infectious virus production and major histocompatibility complex class I molecule expression. Sci Rep, 5, 2015, 13994.
13. 13 Kachko, A., Frey, S.E., Sirota, L., Ray, R., Wells, F., Zubkova, I., Zhang, P., Major, M.E., Antibodies to an interfering epitope in hepatitis C virus E2 can mask vaccine-induced neutralizing activity. Hepatology 62 (2015), 1670–1682.
14. 14 Tarr, A.W., Urbanowicz, R.A., Jayaraj, D., Brown, R.J., McKeating, J.A., Irving, W.L., Ball, J.K., Naturally occurring antibodies that recognize linear epitopes in the amino terminus of the hepatitis C virus E2 protein confer noninterfering, additive neutralization. J Virol 86 (2012), 2739–2749.
15. 15 Keck, Z., Wang, W., Wang, Y., Lau, P., Carlsen, T.H., Prentoe, J., Xia, J., Patel, A.H., Bukh, J., Foung, S.K., Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus E2 glycoprotein. J Virol 87 (2013), 37–51.
16. 16 Keck, Z.Y., Girard-Blanc, C., Wang, W., Lau, P., Zuiani, A., Rey, F.A., Krey, T., Diamond, M.S., Foung, S.K., Antibody response to hypervariable region 1 interferes with broadly neutralizing antibodies to hepatitis C virus. J Virol 90 (2016), 3112–3122.
17. 17 Smith, D.B., Bukh, J., Kuiken, C., Muerhoff, A.S., Rice, C.M., Stapleton, J.T., Simmonds, P., Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 59 (2014), 318–327.
18. 18 Messina, J.P., Humphreys, I., Flaxman, A., Brown, A., Cooke, G.S., Pybus, O.G., Barnes, E., Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 61 (2015), 77–87.
19. 19• von Hahn, T., Yoon, J.C., Alter, H., Rice, C.M., Rehermann, B., Balfe, P., McKeating, J.A., Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology 132 (2007), 667–678 Demonstrates evolving viral escape from antibody responses over 26 years of HCV infection.
20. 20 Tarr, A.W., Khera, T., Hueging, K., Sheldon, J., Steinmann, E., Pietschmann, T., Brown, R.J., Genetic diversity underlying the envelope glycoproteins of hepatitis C virus: structural and functional consequences and the implications for vaccine design. Viruses 7 (2015), 3995–4046.
21. 21 Owsianka, A., Tarr, A.W., Juttla, V.S., Lavillette, D., Bartosch, B., Cosset, F.L., Ball, J.K., Patel, A.H., Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. J Virol 79 (2005), 11095–11104.
22. 22 Broering, T.J., Garrity, K.A., Boatright, N.K., Sloan, S.E., Sandor, F., Thomas, W.D. Jr., Szabo, G., Finberg, R.W., Ambrosino, D.M., Babcock, G.J., Identification and characterization of broadly neutralizing human monoclonal antibodies directed against the E2 envelope glycoprotein of hepatitis C virus. J Virol 83 (2009), 12473–12482.
23. 23 Lavie, M., Sarrazin, S., Montserret, R., Descamps, V., Baumert, T.F., Duverlie, G., Seron, K., Penin, F., Dubuisson, J., Identification of conserved residues in hepatitis C virus envelope glycoprotein E2 that modulate virus dependence on CD81 and SRB1 entry factors. J Virol 88 (2014), 10584–10597.
24. 24 Farci, P., Shimoda, A., Wong, D., Cabezon, T., De Gioannis, D., Strazzera, A., Shimizu, Y., Shapiro, M., Alter, H.J., Purcell, R.H., Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci U S A 93 (1996), 15394–15399.
25. 25 Ball, J.K., Tarr, A.W., McKeating, J.A., The past, present and future of neutralizing antibodies for hepatitis C virus. Antiviral Res 105 (2014), 100–111.
26. 26 Hadlock, K.G., Lanford, R.E., Perkins, S., Rowe, J., Yang, Q., Levy, S., Pileri, P., Abrignani, S., Foung, S.K., Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes. J Virol 74 (2000), 10407–10416.
27. 27 Johansson, D.X., Voisset, C., Tarr, A.W., Aung, M., Ball, J.K., Dubuisson, J., Persson, M.A., Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus. Proc Natl Acad Sci U S A 104 (2007), 16269–16274.
28. 28• Law, M., Maruyama, T., Lewis, J., Giang, E., Tarr, A.W., Stamataki, Z., Gastaminza, P., Chisari, F.V., Jones, I.M., Fox, R.I., et al. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med 14 (2008), 25–27 Demonstration of a single antibody that protects against HCV infection in vivo, and first report and characterization of AR1, AR2, and AR3 antibodies.
29. 29 Keck, Z.Y., Xia, J., Wang, Y., Wang, W., Krey, T., Prentoe, J., Carlsen, T., Li, A.Y., Patel, A.H., Lemon, S.M., et al. Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate. PLoS Pathog, 8, 2012, e1002653.
30. 30 Tarr, A.W., Owsianka, A.M., Timms, J.M., McClure, C.P., Brown, R.J., Hickling, T.P., Pietschmann, T., Bartenschlager, R., Patel, A.H., Ball, J.K., Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33. Hepatology 43 (2006), 592–601.
31. 31 Sabo, M.C., Luca, V.C., Prentoe, J., Hopcraft, S.E., Blight, K.J., Yi, M., Lemon, S.M., Ball, J.K., Bukh, J., Evans, M.J., et al. Neutralizing monoclonal antibodies against hepatitis C virus E2 protein bind discontinuous epitopes and inhibit infection at a postattachment step. J Virol 85 (2011), 7005–7019.
32. 32 Alhammad, Y., Gu, J., Boo, I., Harrison, D., McCaffrey, K., Vietheer, P.T., Edwards, S., Quinn, C., Coulibaly, F., Poumbourios, P., et al. Monoclonal antibodies directed toward the hepatitis c virus glycoprotein E2 detect antigenic differences modulated by the N-terminal hypervariable region 1 (HVR1), HVR2, and intergenotypic variable region. J Virol 89 (2015), 12245–12261.
33. 33• Tarr, A.W., Lafaye, P., Meredith, L., Damier-Piolle, L., Urbanowicz, R.A., Meola, A., Jestin, J.L., Brown, R.J., McKeating, J.A., Rey, F.A., et al. An alpaca nanobody inhibits hepatitis C virus entry and cell-to-cell transmission. Hepatology 58 (2013), 932–939 Characterization of a single-domain antibody to HCV E2 that is able to prevent HCV cell-to-cell spread.
34. 34 Giang, E., Dorner, M., Prentoe, J.C., Dreux, M., Evans, M.J., Bukh, J., Rice, C.M., Ploss, A., Burton, D.R., Law, M., Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Proc Natl Acad Sci U S A 109 (2012), 6205–6210.
35. 35 Meunier, J.C., Russell, R.S., Goossens, V., Priem, S., Walter, H., Depla, E., Union, A., Faulk, K.N., Bukh, J., Emerson, S.U., et al. Isolation and characterization of broadly neutralizing human monoclonal antibodies to the e1 glycoprotein of hepatitis C virus. J Virol 82 (2008), 966–973.
36. 36 Pileri, P., Uematsu, Y., Campagnoli, S., Galli, G., Falugi, F., Petracca, R., Weiner, A.J., Houghton, M., Rosa, D., Grandi, G., et al. Binding of hepatitis C virus to CD81. Science 282 (1998), 938–941.
37. 37 Bartosch, B., Vitelli, A., Granier, C., Goujon, C., Dubuisson, J., Pascale, S., Scarselli, E., Cortese, R., Nicosia, A., Cosset, F.L., Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J Biol Chem 278 (2003), 41624–41630.
38. 38 Keck, Z.Y., Li, T.K., Xia, J., Bartosch, B., Cosset, F.L., Dubuisson, J., Foung, S.K., Analysis of a highly flexible conformational immunogenic domain a in hepatitis C virus E2. J Virol 79 (2005), 13199–13208.
39. 39 Keck, Z.Y., Op De Beeck, A., Hadlock, K.G., Xia, J., Li, T.K., Dubuisson, J., Foung, S.K., Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions. J Virol 78 (2004), 9224–9232.
40. 40 Owsianka, A.M., Tarr, A.W., Keck, Z.Y., Li, T.K., Witteveldt, J., Adair, R., Foung, S.K., Ball, J.K., Patel, A.H., Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein. J Gen Virol 89 (2008), 653–659.
41. 41 Keck, Z.Y., Li, T.K., Xia, J., Gal-Tanamy, M., Olson, O., Li, S.H., Patel, A.H., Ball, J.K., Lemon, S.M., Foung, S.K., Definition of a conserved immunodominant domain on hepatitis C virus E2 glycoprotein by neutralizing human monoclonal antibodies. J Virol 82 (2008), 6061–6066.
42. 42 Tarr, A.W., Owsianka, A.M., Jayaraj, D., Brown, R.J., Hickling, T.P., Irving, W.L., Patel, A.H., Ball, J.K., Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33. J Gen Virol 88 (2007), 2991–3001.
43. 43 Kong, L., Kadam, R.U., Giang, E., Ruwona, T.B., Nieusma, T., Culhane, J.C., Stanfield, R.L., Dawson, P.E., Wilson, I.A., Law, M., Structure of hepatitis C virus envelope glycoprotein E1 antigenic site 314–324 in complex with antibody IGH526. J Mol Biol 427 (2015), 2617–2628.
44. 44• Kong, L., Giang, E., Robbins, J.B., Stanfield, R.L., Burton, D.R., Wilson, I.A., Law, M., Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1. Proc Natl Acad Sci U S A 109 (2012), 9499–9504 Crystallographic structure of a broadly neutralizing therapeutic antibody in complex with an HCV E2 epitope.
45. 45 Kong, L., Giang, E., Nieusma, T., Robbins, J.B., Deller, M.C., Stanfield, R.L., Wilson, I.A., Law, M., Structure of hepatitis C virus envelope glycoprotein E2 antigenic site 412 to 423 in complex with antibody AP33. J Virol 86 (2012), 13085–13088.
46. 46 Meola, A., Tarr, A.W., England, P., Meredith, L.W., McClure, C.P., Foung, S.K., McKeating, J.A., Ball, J.K., Rey, F.A., Krey, T., Structural flexibility of a conserved antigenic region in hepatitis C virus glycoprotein E2 recognized by broadly neutralizing antibodies. J Virol 89 (2015), 2170–2181.
47. 47 Li, Y., Pierce, B.G., Wang, Q., Keck, Z.Y., Fuerst, T.R., Foung, S.K., Mariuzza, R.A., Structural basis for penetration of the glycan shield of hepatitis C virus E2 glycoprotein by a broadly neutralizing human antibody. J Biol Chem 290 (2015), 10117–10125.
48. 48 Potter, J.A., Owsianka, A.M., Jeffery, N., Matthews, D.J., Keck, Z.Y., Lau, P., Foung, S.K., Taylor, G.L., Patel, A.H., Toward a hepatitis C virus vaccine: the structural basis of hepatitis C virus neutralization by AP33, a broadly neutralizing antibody. J Virol 86 (2012), 12923–12932.
49. 49 Krey, T., Meola, A., Keck, Z.Y., Damier-Piolle, L., Foung, S.K., Rey, F.A., Structural basis of HCV neutralization by human monoclonal antibodies resistant to viral neutralization escape. PLoS Pathog, 9, 2013, e1003364.
50. 50 Deng, L., Zhong, L., Struble, E., Duan, H., Ma, L., Harman, C., Yan, H., Virata-Theimer, M.L., Zhao, Z., Feinstone, S., et al. Structural evidence for a bifurcated mode of action in the antibody-mediated neutralization of hepatitis C virus. Proc Natl Acad Sci U S A 110 (2013), 7418–7422.
51. 51 Deng, L., Ma, L., Virata-Theimer, M.L., Zhong, L., Yan, H., Zhao, Z., Struble, E., Feinstone, S., Alter, H., Zhang, P., Discrete conformations of epitope II on the hepatitis C virus E2 protein for antibody-mediated neutralization and nonneutralization. Proc Natl Acad Sci U S A 111 (2014), 10690–10695.
52. 52•• Kong, L., Giang, E., Nieusma, T., Kadam, R.U., Cogburn, K.E., Hua, Y., Dai, X., Stanfield, R.L., Burton, D.R., Ward, A.B., et al. Hepatitis C virus E2 envelope glycoprotein core structure. Science 342 (2013), 1090–1094 Crystal structure of HCV E2 glycoprotein core, determined in complex with a broadly neutralizing human antibody.
53. 53•• Khan, A.G., Whidby, J., Miller, M.T., Scarborough, H., Zatorski, A.V., Cygan, A., Price, A.A., Yost, S.A., Bohannon, C.D., Jacob, J., et al. Structure of the core ectodomain of the hepatitis C virus envelope glycoprotein 2. Nature 509 (2014), 381–384 Crystal structure of HCV E2 glycoprotein core, determined in complex with a murine antibody.
54. 54 Pantua, H., Diao, J., Ultsch, M., Hazen, M., Mathieu, M., McCutcheon, K., Takeda, K., Date, S., Cheung, T.K., Phung, Q., et al. Glycan shifting on hepatitis C virus (HCV) E2 glycoprotein is a mechanism for escape from broadly neutralizing antibodies. J Mol Biol 425 (2013), 1899–1914.
55. 55 Castelli, M., Clementi, N., Sautto, G.A., Pfaff, J., Kahle, K.M., Barnes, T., Doranz, B.J., Dal Peraro, M., Clementi, M., Burioni, R., et al. HCV E2 core structures and mAbs: something is still missing. Drug Discov Today 19 (2014), 1964–1970.
56. 56 Khan, A.G., Miller, M.T., Marcotrigiano, J., HCV glycoprotein structures: what to expect from the unexpected. Curr Opin Virol 12 (2015), 53–58.
57. 57• Keck, Z.Y., Li, S.H., Xia, J., von Hahn, T., Balfe, P., McKeating, J.A., Witteveldt, J., Patel, A.H., Alter, H., Rice, C.M., et al. Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity. J Virol 83 (2009), 6149–6160 Characterization of E2 envelope glycoprotein mutants arising over 26 years of HCV infection in an individual, showing evidence for escape through mutants distal from antibody and CD81 binding sites.
58. 58 Fafi-Kremer, S., Fofana, I., Soulier, E., Carolla, P., Meuleman, P., Leroux-Roels, G., Patel, A.H., Cosset, F.L., Pessaux, P., Doffoel, M., et al. Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation. J Exp Med 207 (2010), 2019–2031.
59. 59 Fofana, I., Fafi-Kremer, S., Carolla, P., Fauvelle, C., Zahid, M.N., Turek, M., Heydmann, L., Cury, K., Hayer, J., Combet, C., et al. Mutations that alter use of hepatitis C virus cell entry factors mediate escape from neutralizing antibodies. Gastroenterology 143 (2012), 223–233 e229.
60. 60 Gal-Tanamy, M., Keck, Z.Y., Yi, M., McKeating, J.A., Patel, A.H., Foung, S.K., Lemon, S.M., In vitro selection of a neutralization-resistant hepatitis C virus escape mutant. Proc Natl Acad Sci U S A 105 (2008), 19450–19455.
61. 61 Keck, Z.Y., Saha, A., Xia, J., Wang, Y., Lau, P., Krey, T., Rey, F.A., Foung, S.K., Mapping a region of hepatitis C virus E2 that is responsible for escape from neutralizing antibodies and a core CD81-binding region that does not tolerate neutralization escape mutations. J Virol 85 (2011), 10451–10463.
62. 62 Keck, Z.Y., Angus, A.G., Wang, W., Lau, P., Wang, Y., Gatherer, D., Patel, A.H., Foung, S.K., Non-random escape pathways from a broadly neutralizing human monoclonal antibody map to a highly conserved region on the hepatitis C virus E2 glycoprotein encompassing amino acids 412–423. PLoS Pathog, 10, 2014, e1004297.
63. 63• Chung, R.T., Gordon, F.D., Curry, M.P., Schiano, T.D., Emre, S., Corey, K., Markmann, J.F., Hertl, M., Pomposelli, J.J., Pomfret, E.A., et al. Human monoclonal antibody MBL-HCV1 delays HCV viral rebound following liver transplantation: a randomized controlled study. Am J Transplant 13 (2013), 1047–1054 Phase II study of monoclonal antibody HCV1 in HCV patients undergoing liver transplantation, demonstrating HCV escape mutants in humans due to monoclonal antibody pressure.
64. 64 Babcock, G.J., Iyer, S., Smith, H.L., Wang, Y., Rowley, K., Ambrosino, D.M., Zamore, P.D., Pierce, B.G., Molrine, D.C., Weng, Z., High-throughput sequencing analysis of post-liver transplantation HCV E2 glycoprotein evolution in the presence and absence of neutralizing monoclonal antibody. PLOS ONE, 9, 2014, e100325.
65. 65 Morin, T.J., Broering, T.J., Leav, B.A., Blair, B.M., Rowley, K.J., Boucher, E.N., Wang, Y., Cheslock, P.S., Knauber, M., Olsen, D.B., et al. Human monoclonal antibody HCV1 effectively prevents treats HCV infection in chimpanzees. PLoS Pathog, 8, 2012, e1002895.
66. 66 Falkowska, E., Kajumo, F., Garcia, E., Reinus, J., Dragic, T., Hepatitis C virus envelope glycoprotein E2 glycans modulate entry CD81 binding, and neutralization. J Virol 81 (2007), 8072–8079.
67. 67 Helle, F., Goffard, A., Morel, V., Duverlie, G., McKeating, J., Keck, Z.Y., Foung, S., Penin, F., Dubuisson, J., Voisset, C., The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein. J Virol 81 (2007), 8101–8111.
68. 68 Kong, L., Jackson, K.N., Wilson, I.A., Law, M., Capitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine design. Curr Opin Virol 11 (2015), 148–157.
69. 69 de Jong, Y.P., Dorner, M., Mommersteeg, M.C., Xiao, J.W., Balazs, A.B., Robbins, J.B., Winer, B.Y., Gerges, S., Vega, K., Labitt, R.N., et al. Broadly neutralizing antibodies abrogate established hepatitis C virus infection. Sci Transl Med, 6, 2014, 254ra129.
70. 70•• Bailey, J.R., Wasilewski, L.N., Snider, A.E., El-Diwany, R., Osburn, W.O., Keck, Z., Foung, S.K., Ray, S.C., Naturally selected hepatitis C virus polymorphisms confer broad neutralizing antibody resistance. J Clin Invest 125 (2015), 437–447 This study defines a key parameter in the breadth of protection necessary in a B cell based vaccine, and identifies many resistance associated mutants.
71. 71• Urbanowicz, R.A., McClure, C.P., Brown, R.J., Tsoleridis, T., Persson, M.A., Krey, T., Irving, W.L., Ball, J.K., Tarr, A.W., A diverse panel of hepatitis C virus glycoproteins for use in vaccine research reveals extremes of monoclonal antibody neutralization resistance. J Virol 90 (2015), 3288–3301 This study defines the limitations of broadly neutralizing antibodies, and stratifies a range of genotype 1–6 HCV clones based on resistance phenotypes.
72. 72 Guan, M., Wang, W., Liu, X., Tong, Y., Liu, Y., Ren, H., Zhu, S., Dubuisson, J., Baumert, T.F., Zhu, Y., et al. Three different functional microdomains in the hepatitis C virus hypervariable region 1 (HVR1) mediate entry and immune evasion. J Biol Chem 287 (2012), 35631–35645.
73. 73• Prentoe, J., Verhoye, L., Velazquez Moctezuma, R., Buysschaert, C., Farhoudi, A., Wang, R., Alter, H., Meuleman, P., Bukh, J., HVR1-mediated antibody evasion of highly infectious in vivo adapted HCV in humanised mice. Gut, 2015 Using cultured viruses with and without HVR1, this study determines that HVR1 is responsible for genotypic neutralization variability and occlusion for a range of broadly neutralizing antibodies.
74. 74 Leroux-Roels, G., Depla, E., Hulstaert, F., Tobback, L., Dincq, S., Desmet, J., Desombere, I., Maertens, G., A candidate vaccine based on the hepatitis C E1 protein: tolerability and immunogenicity in healthy volunteers. Vaccine 22 (2004), 3080–3086.
75. 75 Alvarez-Lajonchere, L., Shoukry, N.H., Gra, B., Amador-Canizares, Y., Helle, F., Bedard, N., Guerra, I., Drouin, C., Dubuisson, J., Gonzalez-Horta, E.E., et al. Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a Phase I clinical trial. J Viral Hepat 16 (2009), 156–167.
76. 76 Colombatto, P., Brunetto, M.R., Maina, A.M., Romagnoli, V., Almasio, P., Rumi, M.G., Ascione, A., Pinzello, G., Mondelli, M., Muratori, L., et al. HCV E1E2-MF59 vaccine in chronic hepatitis C patients treated with PEG-IFNalpha2a and Ribavirin: a randomized controlled trial. J Viral Hepat 21 (2014), 458–465.
77. 77 Frey, S.E., Houghton, M., Coates, S., Abrignani, S., Chien, D., Rosa, D., Pileri, P., Ray, R., Di Bisceglie, A.M., Rinella, P., et al. Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine 28 (2010), 6367–6373.
78. 78 Wong, J.A., Bhat, R., Hockman, D., Logan, M., Chen, C., Levin, A., Frey, S.E., Belshe, R.B., Tyrrell, D.L., Law, J.L., et al. Recombinant hepatitis C virus envelope glycoprotein vaccine elicits antibodies targeting multiple epitopes on the envelope glycoproteins associated with broad cross-neutralization. J Virol 88 (2014), 14278–14288.
79. 79 Folgori, A., Capone, S., Ruggeri, L., Meola, A., Sporeno, E., Ercole, B.B., Pezzanera, M., Tafi, R., Arcuri, M., Fattori, E., et al. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat Med 12 (2006), 190–197.
80. 80 Kelly, C., Swadling, L., Capone, S., Brown, A., Richardson, R., Halliday, J., von Delft, A., Oo, Y., Mutimer, D., Kurioka, A., et al. Chronic hepatitis C viral infection subverts vaccine-induced T-cell immunity in humans. Hepatology 63 (2016), 1455–1470.
81. 81 Elmowalid, G.A., Qiao, M., Jeong, S.H., Borg, B.B., Baumert, T.F., Sapp, R.K., Hu, Z., Murthy, K., Liang, T.J., Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. Proc Natl Acad Sci U S A 104 (2007), 8427–8432.
82. 82 Correia, B.E., Bates, J.T., Loomis, R.J., Baneyx, G., Carrico, C., Jardine, J.G., Rupert, P., Correnti, C., Kalyuzhniy, O., Vittal, V., et al. Proof of principle for epitope-focused vaccine design. Nature 507 (2014), 201–206.
83. 83 Jardine, J., Julien, J.P., Menis, S., Ota, T., Kalyuzhniy, O., McGuire, A., Sok, D., Huang, P.S., MacPherson, S., Jones, M., et al. Rational HIV immunogen design to target specific germline B cell receptors. Science 340 (2013), 711–716.
84. 84 McLellan, J.S., Chen, M., Joyce, M.G., Sastry, M., Stewart-Jones, G.B., Yang, Y., Zhang, B., Chen, L., Srivatsan, S., Zheng, A., et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 342 (2013), 592–598.
85. 85 Yassine, H.M., Boyington, J.C., McTamney, P.M., Wei, C.J., Kanekiyo, M., Kong, W.P., Gallagher, J.R., Wang, L., Zhang, Y., Joyce, M.G., et al. Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nat Med 21 (2015), 1065–1070.
86. 86 Ruwona, T.B., Giang, E., Nieusma, T., Law, M., Fine mapping of murine antibody responses to immunization with a novel soluble form of hepatitis C virus envelope glycoprotein complex. J Virol 88 (2014), 10459–10471.
87. 87 Ren, Y., Min, Y.Q., Liu, M., Chi, L., Zhao, P., Zhang, X.L., N-glycosylation-mutated HCV envelope glycoprotein complex enhances antigen-presenting activity and cellular and neutralizing antibody responses. Biochim Biophys Acta, 2015.
88. 88 Sandomenico, A., Leonardi, A., Berisio, R., Sanguigno, L., Foca, G., Foca, A., Ruggiero, A., Doti, N., Muscariello, L., Barone, D., et al. Generation and characterization of monoclonal antibodies against a cyclic variant of hepatitis C virus E2 epitope 412–422. J Virol 90 (2016), 3745–3759.
89. 89• He, L., Cheng, Y., Kong, L., Azadnia, P., Giang, E., Kim, J., Wood, M.R., Wilson, I.A., Law, M., Zhu, J., Approaching rational epitope vaccine design for hepatitis C virus with meta-server and multivalent scaffolding. Sci Rep, 5, 2015, 12501 First reported epitope-based rational design of HCV immunogens.
90. 90 Falson, P., Bartosch, B., Alsaleh, K., Tews, B.A., Loquet, A., Ciczora, Y., Riva, L., Montigny, C., Montpellier, C., Duverlie, G., et al. Hepatitis C virus envelope glycoprotein E1 forms trimers at the surface of the virion. J Virol 89 (2015), 10333–10346.
91. 91 Sanders, R.W., Derking, R., Cupo, A., Julien, J.P., Yasmeen, A., de Val, N., Kim, H.J., Blattner, C., de la Pena, A.T., Korzun, J., et al. A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog, 9, 2013, e1003618.
92. 92 Julien, J.P., Cupo, A., Sok, D., Stanfield, R.L., Lyumkis, D., Deller, M.C., Klasse, P.J., Burton, D.R., Sanders, R.W., Moore, J.P., et al. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 342 (2013), 1477–1483.
93. 93 Zhou, T., Lynch, R.M., Chen, L., Acharya, P., Wu, X., Doria-Rose, N.A., Joyce, M.G., Lingwood, D., Soto, C., Bailer, R.T., et al. Structural repertoire of HIV-1-neutralizing antibodies targeting the CD4 supersite in 14 donors. Cell 161 (2015), 1280–1292.
94. 94 Crooks, G.E., Hon, G., Chandonia, J.M., Brenner, S.E., WebLogo: a sequence logo generator. Genome Res 14 (2004), 1188–1190.
95. 95 Kuiken, C., Yusim, K., Boykin, L., Richardson, R., The Los Alamos hepatitis C sequence database. Bioinformatics 21 (2005), 379–384.
96. 96 Leaver-Fay, A., Tyka, M., Lewis, S.M., Lange, O.F., Thompson, J., Jacak, R., Kaufman, K., Renfrew, P.D., Smith, C.A., Sheffler, W., et al. ROSETTA3: an object-oriented software suite for the simulation and design of macromolecules. Methods Enzymol 487 (2011), 545–574.
97. 97 Drummer, H.E., Challenges to the development of vaccines to hepatitis C virus that elicit neutralizing antibodies. Front Microbiol, 5, 2014, 329.
98. 98 Wasilewski, L.N., El-Diwany, R., Munshaw, S., Snider, A.E., Brady, J.K., Osburn, W.O., Ray, S.C., Bailey, J.R., A hepatitis C virus envelope polymorphism confers resistance to neutralization by polyclonal sera and broadly neutralizing monoclonal antibodies. J Virol 90 (2016), 3773–3782.